SCHEMBL1339414

SCHEMBL1339414

CCOCc1cc(-c2ccc3c(c2)c2cc(-c4ccc(Cl)cc4Cl)c(=O)n(C)c2n3C)[nH]n1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GABRG2 P18507 6/20 0.43
▸ GABRB3 P28472 6/20 0.43
▸ GABRA5 P31644 6/20 0.43
▸ GABRA1 P14867 5/20 0.43
▸ CNR1 P21554 7/20 0.33
▸ CNR2 P34972 7/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ HSD11B1 P28845 1/20 0.31
▸ PLK1 P53350 1/20 0.31
▸ MAPK8 P45983 1/20 0.31
▸ MAPK9 P45984 1/20 0.31
▸ MAPK10 P53779 1/20 0.31
▸ RIPK2 O43353 1/20 0.31
▸ NOD2 Q9HC29 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1338782 0.88 CNR1 (0.37) GABRA1CNR1CNR2KDM4EALDH1A1
SCHEMBL1338161 0.86 CNR1 (0.35) GABRG2GABRB3GABRA5GABRA1CNR1
SCHEMBL3126783 0.84 GABRA1 (0.36) GABRG2GABRB3GABRA5GABRA1KDM4E
SCHEMBL1339069 0.84 GABRA1 (0.36) GABRG2GABRB3GABRA5GABRA1KDM4E
SCHEMBL1336848 0.84 CNR1 (0.38) GABRA1CNR1CNR2KDM4EALDH1A1
Hydrochloric Acid SCHEMBL1339338 0.83 GABRA1 (0.35) GABRG2GABRB3GABRA5GABRA1
SCHEMBL1339434 0.83 CNR1 (0.36) CNR1CNR2
SCHEMBL1338017 0.83 GABRA1 (0.43) GABRG2GABRB3GABRA5GABRA1CNR1
SCHEMBL1339276 0.83 MKNK1 (0.43) GABRA1CNR1CNR2KDM4EALDH1A1
SCHEMBL1336811 0.82 P2RX3 (0.32) CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed
EP-1940840-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 — — EP disclosed
WO-2007045758-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 GABRG2 1617/4885GABRB3 1017/4885GABRA5 1253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback